HC Wainwright Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to "Buy"

HC Wainwright upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) from a neutral rating to a buy rating in a research note released on Monday morning, Marketbeat.com reports. The firm currently has $20.00 target price on the biotechnology company's stock.

A number of other equities analysts have also weighed in on ACRS. BTIG Research upgraded shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price target on the stock in a research report on Tuesday, November 19th. Leerink Partnrs upgraded Aclaris Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 19th. Jefferies Financial Group upgraded Aclaris Therapeutics from a "hold" rating to a "buy" rating and upped their price target for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. StockNews.com upgraded Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Piper Sandler upgraded Aclaris Therapeutics from a "neutral" rating to an "overweight" rating and upped their target price for the company from $3.00 to $13.00 in a report on Monday, November 18th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics currently has an average rating of "Buy" and an average price target of $11.00.

Aclaris Therapeutics Trading Up 6.3 %

NASDAQ:ACRS traded up $0.17 during trading hours on Monday, hitting $2.89. 1,790,514 shares of the stock were exchanged, compared to its average volume of 1,388,451. The company has a market cap of $206.44 million, a P/E ratio of -5.56 and a beta of 0.44. The firm's fifty day moving average price is $2.72 and its 200 day moving average price is $1.74. Aclaris Therapeutics has a 52-week low of $0.86 and a 52-week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Equities analysts expect that Aclaris Therapeutics will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling at Aclaris Therapeutics

In related news, Director Anand Mehra acquired 666,666 shares of the firm's stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the acquisition, the director now owns 710,030 shares in the company, valued at $1,597,567.50. The trade was a 1,537.37 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Stonepine Capital Management LLC acquired a new stake in Aclaris Therapeutics in the second quarter valued at approximately $2,120,000. Trium Capital LLP purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at approximately $2,081,000. BML Capital Management LLC raised its holdings in shares of Aclaris Therapeutics by 9.7% in the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company's stock valued at $16,388,000 after purchasing an additional 1,261,866 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aclaris Therapeutics during the 3rd quarter worth $1,053,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Aclaris Therapeutics by 187.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company's stock worth $382,000 after purchasing an additional 216,826 shares in the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.